Works matching DE "DOLUTEGRAVIR"
Results: 206
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients.
- Published in:
- Journal of Medical Virology, 2021, v. 93, n. 12, p. 6557, doi. 10.1002/jmv.27195
- By:
- Publication type:
- Article
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-023-51144-7
- By:
- Publication type:
- Article
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 8, p. 1877, doi. 10.1007/s40121-024-01008-y
- By:
- Publication type:
- Article
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 891, doi. 10.1007/s40121-024-00961-y
- By:
- Publication type:
- Article
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 875, doi. 10.1007/s40121-024-00950-1
- By:
- Publication type:
- Article
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 11, p. 2581, doi. 10.1007/s40121-023-00879-x
- By:
- Publication type:
- Article
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 8, p. 2117, doi. 10.1007/s40121-023-00848-4
- By:
- Publication type:
- Article
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 2051, doi. 10.1007/s40121-021-00522-7
- By:
- Publication type:
- Article
Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1294579
- By:
- Publication type:
- Article
Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1238587
- By:
- Publication type:
- Article
FORMULATION AND EVALUATION OF DOLUTEGRAVIR SODIUM NANOEMULSION FOR THE TREATMENT OF HIV.
- Published in:
- Pharmacophore, 2022, v. 13, n. 6, p. 1, doi. 10.51847/gnVuQuUCIf
- By:
- Publication type:
- Article
STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF RELATED SUBSTANCES FOR DOLUTEGRAVIR DISPERSIBLE TABLETS.
- Published in:
- Pharmacophore, 2022, v. 13, n. 2, p. 56, doi. 10.51847/2MarzXSiL2
- By:
- Publication type:
- Article
Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/ cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up.
- Published in:
- Infection & Chemotherapy, 2024, v. 56, n. 2, p. 247, doi. 10.3947/ic.2024.0006
- By:
- Publication type:
- Article
A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.
- Published in:
- Infection & Chemotherapy, 2023, v. 55, n. 3, p. 337, doi. 10.3947/ic.2022.0176
- By:
- Publication type:
- Article
A Korean Post-Marketing Surveillance Study of Dolutegravir Single-Agent Tablets in Patients with HIV-1.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, n. 4, p. 711, doi. 10.3947/ic.2022.0058
- By:
- Publication type:
- Article
Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine(DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 272
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 271
- By:
- Publication type:
- Article
Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants.
- Published in:
- Viruses (1999-4915), 2025, v. 17, n. 1, p. 121, doi. 10.3390/v17010121
- By:
- Publication type:
- Article
The Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations.
- Published in:
- International Journal of Analytical Chemistry, 2022, p. 1, doi. 10.1155/2022/3510277
- By:
- Publication type:
- Article
Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
- Published in:
- PLoS ONE, 2021, v. 16, n. 2, p. 1, doi. 10.1371/journal.pone.0246994
- By:
- Publication type:
- Article
Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV.
- Published in:
- PLoS ONE, 2020, v. 15, n. 8, p. 1, doi. 10.1371/journal.pone.0238052
- By:
- Publication type:
- Article
Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir.
- Published in:
- Drug Target Insights, 2023, v. 17, n. 1, p. 45, doi. 10.33393/dti.2023.2529
- By:
- Publication type:
- Article
The rollout of paediatric dolutegravir and virological outcomes among children living with HIV in Mozambique.
- Published in:
- Southern African Journal of HIV Medicine, 2024, v. 25, n. 1, p. 1, doi. 10.4102/sajhivmed.v25i1.1578
- By:
- Publication type:
- Article
Virologic outcomes with tenofovir-lamivudinedolutegravir in adults failing PI-based second-line ART.
- Published in:
- Southern African Journal of HIV Medicine, 2024, v. 25, n. 1, p. 1, doi. 10.4102/sajhivmed.v25i1.1567
- By:
- Publication type:
- Article
Dolutegravir resistance in three pregnant and breastfeeding women in South Africa.
- Published in:
- Southern African Journal of HIV Medicine, 2023, v. 24, n. 1, p. 1, doi. 10.4102/sajhivmed.v24i1.1531
- By:
- Publication type:
- Article
Weight gain on dolutegravir: Association is not the same as causation.
- Published in:
- Southern African Journal of HIV Medicine, 2023, v. 24, n. 1, p. 1, doi. 10.4102/sajhivmed.v24i1.1500
- By:
- Publication type:
- Article
Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV.
- Published in:
- Southern African Journal of HIV Medicine, 2022, v. 23, n. 1, p. 1, doi. 10.4102/sajhivmed.v23i1.1452
- By:
- Publication type:
- Article
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe.
- Published in:
- Southern African Journal of HIV Medicine, 2022, v. 23, n. 1, p. 1, doi. 10.4102/sajhivmed.v23i1.1435
- By:
- Publication type:
- Article
Dolutegravir for second-line treatment: Programmatic implications of new evidence.
- Published in:
- Southern African Journal of HIV Medicine, 2022, v. 23, n. 1, p. 1, doi. 10.4102/sajhivmed.v23i1.1428
- By:
- Publication type:
- Article
HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey.
- Published in:
- Virology Journal, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12985-023-02245-2
- By:
- Publication type:
- Article
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
- Published in:
- BMC Women's Health, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12905-023-02630-7
- By:
- Publication type:
- Article
Study of Dolutegravir Degradation and Spectroscopic Identification of Products by LCMS, <sup>1</sup>H and <sup>13</sup>C NMR Techniques.
- Published in:
- Pharmaceutical Chemistry Journal, 2019, v. 53, n. 4, p. 368, doi. 10.1007/s11094-019-02007-x
- By:
- Publication type:
- Article
Brief psychotic episode in a patient living with HIV and treated with dolutegravir. Much more common tan we thought? A case report and review.
- Published in:
- European Psychiatry, 2020, v. 63, p. S348
- By:
- Publication type:
- Article
Synthesis of Three Key Impurities of Drug Dolutegravir: An Inhibitor of HIV-1 Integrase.
- Published in:
- Polycyclic Aromatic Compounds, 2023, v. 43, n. 4, p. 3706, doi. 10.1080/10406638.2022.2077772
- By:
- Publication type:
- Article
Practical and Efficient Route to Dolutegravir Sodium via One-Pot Synthesis of Key Intermediate with Controlled Formation of Impurities.
- Published in:
- Russian Journal of Organic Chemistry, 2022, v. 58, n. 4, p. 526, doi. 10.1134/S1070428022040091
- By:
- Publication type:
- Article
Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 11, p. 1841, doi. 10.3390/cells11111841
- By:
- Publication type:
- Article
Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia.
- Published in:
- Integrated Pharmacy Research & Practice, 2024, v. 13, p. 31, doi. 10.2147/IPRP.S455351
- By:
- Publication type:
- Article
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
- Published in:
- Patient Preference & Adherence, 2022, v. 16, p. 3267, doi. 10.2147/PPA.S379065
- By:
- Publication type:
- Article
Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting.
- Published in:
- Patient Preference & Adherence, 2021, v. 15, p. 1177, doi. 10.2147/PPA.S308571
- By:
- Publication type:
- Article
Targeted solutions to increase dolutegravir coverage, viral load testing coverage, and viral suppression among children living with HIV in Togo: An analysis of routine facility data.
- Published in:
- PLoS ONE, 2023, v. 18, n. 12, p. 1, doi. 10.1371/journal.pone.0296293
- By:
- Publication type:
- Article
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
- Published in:
- PLoS ONE, 2023, v. 18, n. 9, p. 1, doi. 10.1371/journal.pone.0291480
- By:
- Publication type:
- Article
High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
- Published in:
- PLoS ONE, 2023, v. 17, n. 5, p. 1, doi. 10.1371/journal.pone.0284767
- By:
- Publication type:
- Article
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
- Published in:
- PLoS ONE, 2023, v. 17, n. 1, p. 1, doi. 10.1371/journal.pone.0279996
- By:
- Publication type:
- Article
Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 4, p. 401, doi. 10.1177/10600280211038504
- By:
- Publication type:
- Article
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 4, p. 412, doi. 10.1177/10600280211034176
- By:
- Publication type:
- Article
Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 4, p. 1100, doi. 10.1002/cpt.3370
- By:
- Publication type:
- Article
Intranasal Administration of Dolutegravir-Loaded Nanoemulsion-Based In Situ Gel for Enhanced Bioavailability and Direct Brain Targeting.
- Published in:
- Gels (2310-2861), 2023, v. 9, n. 2, p. 130, doi. 10.3390/gels9020130
- By:
- Publication type:
- Article
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 11, p. 1924, doi. 10.1002/psp4.13251
- By:
- Publication type:
- Article
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2024, v. 16, p. 133, doi. 10.2147/HIV.S452130
- By:
- Publication type:
- Article